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Introduction
Chromatin is organized into distinct regions that are defined
by their biochemical environment. Intricate protein networks
are involved in maintaining chromatin structure and function,
and DNA can adopt distinct secondary structures besides the
standard B-DNA helix ;[1] this adds to the structural repertoire
controlling the functionality of chromatin. Certain G-rich se-
quences can adopt supramolecular structures called G-quadru-
plexes, which comprise tetrads of Hoogsteen hydrogen-bond-
ed guanines that stack with p–p interactions. These structures
are stabilized by monovalent cations such as Na+ and K+ in
the central electron-rich channel. The conformations of the
strands and loops connecting the tetrads vary, depending on
the nucleic acid primary sequence and factors such as strand
number, salt composition, and concentration.[2] Genome-wide
analyses have revealed that putative G-quadruplex sequences
are abundant in the human genome, with enrichment in pro-
moter regions.[3] They are also found at telomeres, which con-
tain the repetitive G-rich sequence (TTAGGG)n that can fold
into G-quadruplexes.[4] This suggests that these elements play
important roles in controlling gene expression[5] and telomere
maintenance. In a seminal paper, Zahler et al. demonstrated
the formation of G-quadruplexes from telomeric sequences in
vitro, thus rendering them resistant to extension by the reverse
transcriptase telomerase.[6] In addition, G-rich RNA can also fold
into G-quadruplexes, and these might be important for the
control of gene expression (e.g. , translation, unsilencing im-
printed genes) and telomere maintenance. G-quadruplex-inter-
acting molecules can stabilize RNA G-quadruplexes, and this
can lead to down-regulation of translation, thus implicating
them as regulatory elements.[7] RNA G-quadruplexes thus cer-
tainly constitute interesting structures with possible biological
consequences.[8]
Recent evidence supports the formation of G-quadruplexes
in vivo, including nucleic acid pull-down strategies,[9] in vivo la-
beling and genome-wide sequencing with small molecules,[10]
and the use of specific antibodies. A recent report describing
the visualization of RNA G-quadruplexes in the cytoplasm of
human cells, and this might provide new avenues to study
RNA G-quadruplexes and their effects on RNA secondary struc-
ture. This approach can be used to monitor the effects of small
molecules on RNA G-quadruplexes in cells.[7c,11] Indeed, small
molecules have proven to be formidable tools to study G-
quadruplexes. They can exert various effects on cells, including
gene expression patterns,[5b] induction of telomere shorten-
ing[12] and uncapping,[13] and induction of DNA damage.[10,13b]
Whereas the DNA damage response can be activated through
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telomere uncapping,[14] genome-wide analysis of the DNA
damage response marker gH2A.X upon treatment with the G-
quadruplex interactor pyridostatin revealed hotspots dispersed
over genomic DNA that contains clusters of putative G-quadru-
plex-forming sequences.[10] Given the possible involvement of
G-quadruplexes in a plethora of biological processes, there is
scope for the development of therapeutic agents based on G-
quadruplex ligands, in order to interfere with these processes
in pathological situations.[15]
Most of the molecules designed to interact with G-quadru-
plexes comprise an electron-poor flat aromatic surface sur-
rounded by cationic charges,[16] in order to target the external
tetrads of the nucleic acid structure,[13b,17] thereby putting for-
ward the notion that such small molecules should ideally be
flat and aromatic in nature. However, an increasing number of
ligands have been reported with alternative modes of inter-
action, for instance a chiral cyclic helicene,[18] distamycin A (and
some of its derivatives), which was shown by NMR spectrosco-
py to be quadruplex groove binders,[19] the loop-binder
DODC,[20] the groove binder Toxapy,[21] binol derivatives,[22]
supramolecular complexes,[23] and synthetic G-quartets.[24] In
order to exploit such interactions further, foldamers have
emerged as an interesting class of compounds, as they are
able to adopt well-defined structures stabilized by non-cova-
lent interactions mimicking the structures of biopolymers.[25]
Examples of foldamers that have been developed for biological
applications such as G-quadruplex binding include peptidic
nucleic acids (PNA), peptoids, and b, g, d, and e peptides.[26]
These molecules are small-to-medium sized, often resistant to
proteolytic cleavage,[27] and show good cell permeability.[28]
Previously, we reported a quinoline-based macrocycle 1 and
dimeric and tetrameric foldamers 2 and 3 (Scheme 1) as G-
quadruplex-interacting molecules.[29] Macrocycle 1 was a very
potent ligand and falls into the category of planar aromatic
compounds with positive cationic side chains. In contrast, tet-
rameric foldamer 3 is helical, (i.e. , non planar), yet it also dis-
played remarkable stabilization of the human telomeric G-
quadruplex and the c-kit promoter G-quadruplex. These inter-
actions were shown to depend on helix handedness, as CD
experiments revealed that they resulted in a preferred helix
sense for 3. Subsequently, we dissected the interactions of aro-
matic oligoamide foldamers with nucleic acids by using direct-
ed DNA evolution against a helical cationic foldamer. We con-
firmed that G-quadruplexes stand as preferred targets and
found that foldamers specifically interact with the backbones
of G-quadruplexes (loops or grooves) as opposed to the top or
Scheme 1. Macrocycles and foldamers synthesized for this study, derived from 8-amino-quinolinecarboxylic acids and 5-aminomethyl-pyridinecarboxylic acid.
Some secondary amide structures are shown as cis conformers for clarity but exist as trans conformers in the folded helices.
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bottom tetrads.[30] We also observed preference for DNA–
quadruplex binding over RNA–quadruplex binding, and noted
foldamer helix handedness and sequence dependence of the
foldamer–quadruplex interaction.[30] Thus, macrocyclic and
folded helical oligoamides selectively interact with G-quadru-
plexes[17c,29, 30]
Inspired by studies showing that derivatives of G-quadruplex
ligands can be better than the lead structures[12,31] and that
controlled folding of a small molecule can enhance G-quadru-
plex selectivity,[32] we endeavored to synthesize a new series of
aromatic amide ligands: nine helical foldamers and a macrocy-
cle. We evaluated their ability to stabilize the human telomeric
G-quadruplex and a number of promoter G-quadruplexes by
using FRET, and we investigated the interactions of two of the
best foldamers further by single-molecule FRET. This method
has the merit that it allows comparison to other well-estab-
lished G-quadruplex ligands. We demonstrate that our new
molecules interact specifically with G-quadruplex DNA (over
duplex DNA) and compare favorably with the best G-quadru-
plex-stabilizing molecules reported so far.[13b,29] Interestingly,
we found that some of the synthesized helical foldamers
showed better stabilization potential than macrocycles in this
family.
Results and Discussion
Synthesis and design of small molecules
We previously reported the syntheses of macrocycle 1, dimeric
and tetrameric foldamers 2 and 3,[29] and foldamers 4[33] and
5.[34] All are based on quinolinecarboxamide sequences. Macro-
cycle 1 and dimer 2 adopt a flat conformation,[35] whereas a hel-
ical conformation is adopted by tetramers 3 and 5 (1.5 turns)
and octamer 4 (over three turns). For the purpose of this
study, we synthesized another macrocycle (6) to compare it to
1. Macrocycle 6 has the same ring atom number as 1, but one
of the quinolines is replaced by an aminomethylpyridine deriv-
ative that was prepared using a previously described proce-
dure.[34, 36] The preparation of 1 involved the low-yielding direct
cyclotrimerization of a monomer precursor, a scheme that
allows the assembly of only three copies of the same mono-
mer. In contrast, the preparation of macrocycle 6 involved the
high-yielding cyclization of an isolated trimeric non-cyclic pre-
cursor. This new scheme is compatible with the sequential in-
corporation of different monomers. The yield of cyclization is
enhanced by the high nucleophilicity of the benzylic amine in
this step (see Supporting Information). The exact conformation
of the resulting macrocycle was not investigated; it might
adopt a planar conformation, but a distortion at the additional
sp3 center might also favor nonplaner states, as observed in
a related herringbone helical foldamer.[36]
Inspired by our previous report of the promising ability of
the tetrameric foldamer 3[29] to selectively stabilize G-quadru-
plex DNA, we varied its C-terminal group R2 and the nature of
the side chains R1 to generate tetrameric foldamers 7–9, and
assessed the effects on G-quadruplex stabilization. The Boc-
protected precursor of ester 7 was converted to the precursor
of acid 3 by saponification, and also to the precursor of secon-
dary amide 8 by using excess methylamine (see the Support-
ing Information). Side-chain deprotection of these precursors
with trifluoroacetic acid (TFA) yielded 3, 7, and 8. Compound 9
was synthesized by converting the propylammonium side
chains of 7 to guanidinium by using 1H-pyrazol-1-carboxamide
hydrochloride. The rationale was to create a side chain with
a delocalized cationic charge, which might allow the formation
of an arginine fork motif with the phosphate groups of the
nucleic acid backbones of the loops and grooves of G-quadru-
plexes.[37]
Next, we synthesized tetramer 10 with alternating quinoline
and methylaminopyridine building blocks by using simple cou-
pling strategies (see the Supporting Information). This type of
backbone can fold in a similar manner as homo-quinoline mul-
timers, but with decreased stability. We did not synthesize
homo-methylaminopyridine multimers as these species do not
fold in organic solvents[36] or water.[34] In order to assess the
effect of foldamer length on G-quadruplex recognition, we
also synthesized the octameric foldamers 11 and 12 (see the
Supporting Information), which carry cationic and anionic side
chains potentially to introduce selectivity. These two molecules
were made from quinoline building blocks but differ in the
sequences of the side-chain substitutions. These synthetic pro-
cedures highlight how complex foldamers can be synthesized
in a few steps in good yield.
FRET melting analyses
We assessed the interactions of the molecules with G-quadru-
plex DNA by employing the FRET melting assay of Mergny and
Maurizot.[38] This assay is widely established in the field to
assess the potency of G-quadruplex ligands and is thus a good
method to compare novel molecules with the plethora of re-
ported ligands. It proved to be an efficient method to investi-
gate our family of foldamers as G-quadruplex ligands in com-
parison with other studies. We focused on DNA quadruplex
sequences and used the human telomeric G-quadruplex (H-
telo)[6] and the sequences of the promoter quadruplexes of
a selection of genes: c-kit (which contains the two G-quadru-
plex sequences c-kit1[39] and c-kit2[40]), c-myc,[5b, 41] bcl2,[42] and k-
ras.[43] These sequences differ in composition, number of nucle-
otides in each loop, and they adopt different quadruplex con-
formations, thus potentially allowing differential recognition by
small molecules that do not target the tetrads per se. As a con-
trol we used a sequence that forms duplex DNA in solution.
We labeled each of these sequences with 6-carboxyfluorescein
(FAM) and 6-carboxytetramethylrhodamine (TAMRA) at the 5’-
and 3’-ends, respectively. Melting of G-quadruplexes results in
an increase in the distance between the fluorophores, and this
can be measured by changes in the FRET signal. We measured
the changes in melting temperature (DTm) upon varying the
concentration of added foldamer or macrocyle (DTm in pres-
ence of 1 mm ligand in Table 1; concentrations for maximal
stabilization in Table 2; full melting profiles in the Supporting
Information).
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Because of differences in sequence and structure, the vari-
ous G-quadruplexes exhibited different Tm values. The maximal
DTm values also differed substantially (from 16.2 (c-myc) to
49.6 8C (k-ras) ; Table 1). Changes in melting temperature
(below) provide information about the potential of the ligands
to interact with G-quadruplexes. Nevertheless, the differences
mentioned above, along with the fact that G-quadruplexes can
change conformation upon binding one ligand but not anoth-
er, call for great caution when drawing comparisons. In addi-
tion, interactions between ligands and quadruplexes that do
not lead to quadruplex stabilization were not examined in
these assays.
As a complement to DTm values, we attempted to measure
dissociation constants (Kd) by using surface plasmon resonance
(SPR). However, SPR measurements with DNA sequences at-
tached to the chip failed because of non-specific interactions
between the foldamers and the substrate of the chip. Better
results might be obtained by attaching the foldamers to the
chip.[30] But slow dissociation kinetics, possible quadruplex ag-
gregation, and conformational changes complicated the meas-
urements, which could not be fitted to a simple 1:1 binding
model. Nevertheless, it can reasonably be inferred from the
DTm values that the lowest dis-
sociation constants are in the
low or sub-micromolar range.
Accurate determination of bind-
ing constants would be possible
by using specific techniques
that are beyond the scope of
this study.[44] It should also be
kept in mind that neither Kd nor
DTm values provide sufficient in-
formation to ascertain quadru-
plex binding in cells and the
triggering of a biological re-
sponse.
The results show that all fully
cationic oligomers, whether
cyclic (1, 6), flat and non cyclic
(2), helical (3, 4, 7–10), long (4),
or bearing ammonium or guani-
dinium (9) side chains, showed
good to high stabilization with
DNA quadruplexes and selectivi-
ty against duplex DNA. In con-
trast, the presence of anionic
residues, either alternating with
cationic residues (5, 11) or clus-
tered at one end of a sequence
(12), was strongly detrimental
to DNA binding. Earlier studies
have shown that the high con-
formational stability of helices
does not depend on monomer
sequence.[34] Thus, the different
behaviors cannot be assigned
to different foldamer conforma-
tions resulting from a change in sequence. Instead, electrostat-
ic repulsions between foldamer and DNA negative charges are
probably responsible for this dramatic effect. It is worth noting
that octamer 12 contains a tetrameric cationic N-terminal seg-
ment, which is a good ligand when tested independently. Nev-
ertheless, this compound showed minimal G-quadruplex stabi-
lization; the neighboring negative charges did not allow
strong binding of the cationic segment.
Both macrocycles 1 and 6 strongly stabilized G-quadruplexes
and had minimal effects with duplex DNA, thus confirming ear-
lier results on the stabilization of H-telo by 1.[29] The sp3 center
of 6 appeared not to be an impediment. Data for the two
compounds are overall comparable, but some notable differen-
ces are worth pointing out. Macrocycle 1 displayed a remark-
able stabilization potential for c-kit2 whereas 6 was limited in
this respect. Conversely, 6 fared much better than 1 and
seemed to behave like helical oligomers concerning the stabili-
zation of c-myc. This might be related to the fact that c-myc
adopts an unusual propeller-type parallel-stranded conforma-
tion.[45]
A comparison of flat dimer 2, helical tetramer 3, and helical
octamer 4, revealed a major effect of length. Compound 2
Table 1. DTm in 60 mm K
+ at 1 mm compound in the FRET melting assays.
Ligand Duplex[a] H-Telo c-kit1 c-kit2 c-myc bcl2 k-ras
DTmmax [8C]
[b] 32.81.2 36.11.3 41.01.5 22.80.7 16.21.1 32.10.9 49.61.4
1 0.7 24.0 16.0 21.4 6.2 14.6 7.3
2 0.0 3.6 10.1 4.4 2.1 0.5 2.8
3 1.1 22.4 15.1 17.6 14.3 18.9 20.8
4 3.9 36.5 39.1 21.5 17.0 30.7 48.4
5 0.0 0.5 2.7 0.0 0.2 0.0 0.0
6 1.6 29.0 13.4 4.8 16.4 13.4 10.5
7 1.3 36.4 37.9 16.8 16.4 30.8 24.1
8 0.0 35.1 24.0 15.9 17.0 19.9 14.2
9 0.6 22.1 20.2 9.9 8.5 12.3 18.4
10 3.1 34.8 25.8 21.0 16.5 27.7 26.8
11 0.0 0.0 0.0 0.0 0.0 0.0 0.2
12 0.0 2.8 6.1 2.8 1.4 0.2 1.8
[a] Duplex formed by two complementary strands linked by a hexa(ethylene glycol) loop. [b] This value corre-
sponds to 95.5 8CTm [8C] for quadruplex alone, as 95.5 8C was the maximum measurable temperature.
Table 2. Concentration [mm] required for maximal stabilization in the FRET-melting assays.
Ligand Duplex[a] H-Telo c-kit1 c-kit2 c-myc bcl2 k-ras
1 6.3 4.1 2.9 1.6 8.1 4.6 6.5
2 >10 >10 >10 >10 >10 >10 >10
3 9.7 4.4 4.3 2.9 2.1 4.7 9.0
4 6.10 0.36 0.34 0.8 0.34 0.56 0.69
5 >10 >10 >10 >10 >10 >10 >10
6 >10 1.41 6.01 5.3 1.32 2.29 >10
7 4.70 0.92 1.94 2.0 1.07 1.23 6.83
8 5.23 1.25 3.69 3.1 0.85 3.09 6.42
9 >10 2.4 3.8 5.4 2.2 2.1 4.2
10 6.77 1.18 4.39 1.3 0.77 1.58 5.57
11 >10 >10 >10 >10 >10 >10 >10
12 >10 >10 >10 >10 >10 >10 >10
[a] Duplex formed by two complementary strands linked by a hexa(ethylene glycol) loop.
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exhibited weak stabilization for all G-quadruplex targets; 3 dis-
played very good stabilization (matching or surpassing 1 in
most cases) ; strikingly, octamer 4 stabilized all G-quadruplex
targets (maximal DTm at 1 mm compound; Table 1). The con-
centration required to stabilize these targets by 4 was 0.36–
0.80 mm (Table 2), whereas duplex stabilization was negligible.
Thus this octameric foldamer is by far the most potent G-quad-
ruplex stabilizing ligand in the series, and is comparable to the
most-potent reported small molecules.[13b]
Changing the C-terminal negatively charged carboxylate
function of 3 to a neutral ester (7) or methyl-amide (8) signifi-
cantly enhanced G-quadruplex stabilization in almost all cases,
thus confirming the detrimental effect of negative charges in
side chains. Interestingly, the minor structural difference be-
tween 7 and 8 nevertheless results in some substantial differ-
ences in DTm (c-kit1, Bcl2, and k-ras entries in Table 1). The
ester appears to be more efficient than the methyl-amide.
The introduction of guanidinium side chains on foldamer 9
reduced G-quadruplex targeting efficiency, despite their ability
to form salt bridges with phosphate ions enhanced by biden-
tate hydrogen bonding. However, the DNA melting profiles in
the presence of 9 (see Supporting Information) show that this
foldamer exhibited formidable selectivity for G-quadruplexes
over duplex DNA, even though maximal stabilization occurred
above 1 mm. In this respect, 9 is more selective than all the
other foldamers and macrocycles of this family.
Finally, tetramer 10 showed G-quadruplex stabilization prop-
erties similar to those of tetramer 7. Both are methyl esters
and bear four ammonium side chains, but 10 is much more
flexible and not expected to fold well because of its amino-
methyl-pyridine units.[34] Compared to quinoline rings, these
units have reduced surface area for aromatic stacking. Com-
pound 10 also has an N-terminal ammonium function, but
these features have weak or compensating effects.
Altogether, the FRET melting results demonstrate that we
improved on the G-quadruplex stabilization potential of the
lead compounds 1 and 3. We also showed the selectivity po-
tential of helical oligoamides with various G-quadruplex tar-
gets. This shows that these foldamers constitute a very potent
family of G-quadruplex ligands.
Single-molecule FRET analyses
To further dissect the conformations and dynamics of G-quad-
ruplex DNA with foldamers and to get an insight into the bind-
ing mode, we investigated the interactions of 3 and 4 with the
human telomeric G-quadruplex by single-molecule FRET. We
tethered biotinylated DNA to a PEG-passivated quartz surface
by using the specific biotin–neutravidin interaction (Figure 1).
This technique allows the monitoring of three different con-
formational states of H-telo: unfolded U, and resolvable folded
conformations F1 and F2 (FRET efficiency E=0.43, 0.63 and
0.80, respectively). We reported previously that macrocycle
1 binds tightly to an unfolded telomeric strand, even in the ab-
sence of K+ , and selectively stabilizes conformation F1 over
the naturally favored conformation F2 of the human telomeric
G-quadruplex.[17c] Unlike macrocycle 1, the tetrameric foldamer
3 was unable to fold the human telomeric sequence into a G-
quadruplex in the absence of K+ (Figure 2). Similarly, the octa-
meric foldamer 4 did not induce folding of the sequence into
a G-quadruplex (data not shown).
Addition of 10 mm K+ to the single-stranded human telo-
meric sequence led to the coexistence of two folded confor-
mations (F1 and predominantly F2 ; Figure 3A and B). Subse-
quent addition of 100 nm 3 induced a rapid increase in the
proportion of F1 (Figure 3C). To a lesser extent, 4 behaved in
the same way (data not shown). After 20 min equilibrium was
reached for both foldamers (Figure 3D and E). Strikingly, unlike
as previously observed for 1, the folded state F2 was not com-
pletely shifted to F1 by 3 (Figure 3D), and this was even more
pronounced for 4 (Figure 3E). When free 4 and K+ were re-
moved (Figure 3F), a mixed population of F1 and F2 remained,
thus suggesting a strong stabilizing effect of still-associated
foldamer 4 with the H-Telo G-quadruplex. Together, these data
suggest a remarkably different mode of interaction between
the macrocycle and the helical foldamers tested, and highlight
Figure 1. Single-molecule FRET.
Figure 2. FRET histogram of human telomeric quadruplex: A) unfolded state
in the absence of K+ , and B) in the absence of K+ but upon addition of
100 nm tetramer 3.
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a change in the dynamics of interaction between the tetramer-
ic and octameric foldamer with the human telomeric G-quad-
ruplex. This is in agreement with the shape of the molecules,
which allow (1) or do not allow (4) direct stacking on top of
the G-tetrads. The different behaviors of the helices and of the
macrocycle is also in agreement with earlier circular dichroism
data that suggested that 1 stabilizes the anti-parallel confor-
mation of H-Telo,[29] and that 4 stabilizes the parallel conforma-
tion of all G-quadruplex aptamer sequences to which it was
exposed.[30]
Conclusions
The facile synthesis of a variety of foldamers based on helical
oligoamides enabled us to generate a library of small mole-
cules in a few simple synthetic steps. Most of these molecules
showed very good stabilization for a variety of G-quadruplexes,
as tested by FRET melting experiments. We have established
helical oligoamides as a potent class of G-quadruplex-interact-
ing molecules and showed that their modes of interaction
differ from our previously reported macrocycle, which presum-
ably interacts with the tetrads of the target nucleic acid struc-
ture. The helical foldamers thus possibly interact with the
backbone loops and grooves G-quadruplexes.[17c,30] The nature
of the side chains and foldamer length play important roles in
the stabilization ability of these foldamers with G-quadruplex
nucleic acids. We found that the octameric foldamer 4 was
even more potent than macrocycle 1, thus placing it in the
range of the best molecules reported so far. Given the relative-
ly easy synthetic procedure and the modular nature, this
family of ligands can easily be expanded further to generate
even more potent molecules. As their modes of interaction
with G-quadruplex DNA differ from those of traditional tetrad
binders, this opens new avenues for the further development
of molecules specific for certain G-quadruplex conformations.
Thus, a detailed NMR spectroscopy and crystallographic struc-
tural investigation of a foldamer–quadruplex is currently in
progress. Preliminary results with a co-crystal of 3 and the
model DNA sequence G4T4G4 showed no contact between fol-
damer and G-tetrad.
It should be noted that foldamer/G-quadruplex adducts
might trigger a different signaling response in a cellular envi-
ronment, as compared to traditional tetrad binders, thereby
providing a tool to shed light on G-quadruplex location and
function in the genome. In addition, with the advent of the
development of G-quadruplex-interacting small molecules as
therapeutic agents,[15] and their good cell penetration ability,[28]
these small molecules can potentially be used in biological
assays and exploited for therapeutic development.
Experimental Section
FRET melting experiments: Oligonucleotide stock solutions
(100 mm in MilliQ water) were diluted in potassium cacodylate
(60 mm, pH 7.4) ; FRET experiments were carried out with 200 nm
oligonucleotide. The seven DNA oligonucleotides were dual fluo-
rescently labeled. K-ras is a dual-labeled 32-mer oligonucleotide
quadruplex from the promoter region of human K-ras (5’-FAM-AGG
GCG GTG TGG GAA GAG GGA AGA GGG GGA GG-TAMRA-3’). C-kit1
was a dual-labeled 21-mer oligonucleotide representing one of the
quadruplex-forming regions in the promoter of the human c-kit
oncogene (5’-FAM-GGG AGG GCG CTG GGA GGA GGG-TAMRA-3’).
C-kit2 was a similar dual-labeled 20-mer oligonucleotide (5’-FAM-
GGG CGG GCG CGA GGG AGG GG-TAMRA-3’). H-Telo was a dual-la-
beled 21-mer oligonucleotide, the minimum human telomeric G-
overhang sequence required to fold into an intramolecular quadru-
plex (5’-FAM-GGG TTA GGG TTA GGG TTA GGG-TAMRA-3’). C-myc
was a dual-labeled 22-mer oligonucleotide comprising one of the
quadruplex-forming regions in the promoter of the human c-myc
oncogene (5’-FAM-TGA GGG TGG GTA GGG TGG GTA A-TAMRA-3’).
Bcl2 was a dual-labeled 27-mer oligonucleotide comprising the
quadruplex-forming region in the promoter of human bcl2. (5’-
FAM-CGG GCG CGG GAG GAA GGG GGC GGG AGC-TAMRA-3’). ds-
DNA was a dual-labeled self-complementary 20-mer oligonucleo-
tide with a central polyethylene glycol linker able to fold into
Figure 3. FRET histogram of H-Telo: A) unfolded state in the absence of K+ ,
B) folded in F1 and F2 states upon addition of 10 mm K+ , upon addition of
tetramer 3 after C) 2 min and D) 20 min, E) upon addition of octamer 4 after
20 min, F) 30 min after removing free K+ and 4.
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a hairpin (5’-FAM-TAT AGC TAT A HEG TAT AGC TAT A-TAMRA-3’;
HEG: hexa(ethylene glycol)). The donor fluorophore was FAM, and
the acceptor fluorophore was TAMRA. Dual-labeled DNA (400 nm)
was annealed by heating at 94 8C for 10 min followed by cooling
to room temperature (0.1 Kmin1). 96-Well plates were prepared
by addition of annealed DNA (50 mL) to each well, followed by the
respective molecule (50 mL) at the required concentration. Meas-
urements were made in triplicate with a LightCycler 480 (excitation
483 nm, detection 533 nm; Roche). Analysis of the data was carried
out with OriginPro 7.5 software (OriginLab, Northampton, MA).
Single-molecule FRET: Single-molecule FRET studies were carried
out as described previously.[17c] In brief, prism-type total internal re-
flection fluorescence (TIRF) microscopy was performed (532 nm
laser excitation) to detect the conformation changes of surface-im-
mobilized human telomeric DNA molecules labeled with a Cy5/
TMR FRET pair. The detected intensity of TMR and Cy5 from each
individual H-Telo molecule was used to derive FRET efficiency, and
combined to obtain FRET histograms. Other experimental parame-
ters were as in our previous single-molecule FRET study on H-Telo.
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